Breast cancer and body weight index: the role of L-carnitine in prediction of answer to treatment and outcome of tumor in patients with obesity (review of literature). by Hojouj, M.I.M., et al.
 
ОГЛЯДОВІ СТАТТІ 
МЕДИЧНІ ПЕРСПЕКТИВИ / MEDICNI PERSPEKTIVI 134 








Y.A. Shevchenko  
BREAST CANCER AND BODY WEIGHT INDEX: 
THE ROLE OF L-CARNITINE IN PREDICTION 
OF ANSWER TO TREATMENT AND OUTCOME 
OF TUMOR IN PATIENTS WITH OBESITY 
(review of literature) 
 
SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine» 
Department of oncology and medical radiology 
V. Vernadskii str., 9, Dnipro, 49044, Ukraine 
ГУ «Днепропетровская медицинская академия МЗ Украины» 
кафедра онкологии и медрадиологии 
(зав. – д. мед. н., проф. И.Н. Бондаренко) 
ул. В. Вернадского, 9, Днепр, 49044, Украина 
e-mail: Hojouj@yahoo.com 
Key words: body mass index (BMI), breast cancer (BC), obesity, overall survival, L-carnitine 
Ключевые слова: индекс массы тела (ИМТ), рак молочной железы (РМЖ), ожирение, общая выживаемость, 
L-карнитин 
 
Abstract. Breast cancer and body weight index: the role of L-carnitine in prediction of answer to treatment and 
outcome of tumor in patients with obesity (review of literature). Hojouj M.I.M., Bondarenko I.N., Zavizion V.F., 
Artemenko M.V., Hojouj T.V., Bondarenko Yu.N., Soloviova N.E., Shevchenko Y.A. Increasing the effectiveness 
of antitumor therapy in breast cancer patients who take L-carnitine during preoperative systemic antitumor therapy 
compared with patients receiving standard neoadjuvant systemic antitumor therapy served as a prerequisite for 
studying possible antitumor mechanisms of L-carnitine. The positive effect of L-carnitine is due to the transfer of palm-
n-fatty acid through the inner membrane into the mitochondrial matrix, which contributes to the formation of a 
significant number of ATP molecules. It has also been shown that L-carnitine can have a double protective effect, 
enhancing the energy dynamics of the cell and inhibiting the hyperexcitability of the cell membrane, making it an ideal 
tool for the prevention and treatment of complications of antitumor therapy and concomitant metabolic disorders. This 
work summarizes the results of epidemiological and clinical studies on the use of L-carnitine in the treatment of breast 
cancer. 
 
Реферат. Рак молочной железы и индекс массы тела: роль L-карнитина в прогнозе ответа на лечение и 
исходе опухоли у больных с ожирением (обзор литературы). Ходжуж М.І.М., Бондаренко И.Н., Зави-
зион В.Ф., Артеменко М.В., Ходжуж Т.В., Бондаренко Ю.Н., Соловьева Н.Е., Шевченко Ю.А. Повышение 
эффективности противоопухолевой терапии у больных РМЖ, которые принимают L-карнитин во время 
проведения предоперационной системной противоопухолевой терапии, по сравнению с пациентами, полу-
чающими стандартную неоадъювантную системную противоопухолевую терапию, послужило предпосылкой 
для изучения возможных противоопухолевых механизмов действия L-карнитина. Положительный эффект L-
карнитина обусловлен переносом пальм-н-жирной кислоты через внутреннюю мембрану в матрикс 
митохондрий, что способствует образованию значительного количества молекул АТФ. Также доказано, что 
L-карнитин может иметь двойной защитный эффект, усиливая энергетическую динамику клетки и ингибируя 
гипервозбудимость клеточной мембраны, что делает ее идеальным средством для профилактики и лечения 
осложнений противоопухолевой терапии и сопутствующих метаболических нарушений. В данной работе 
приведены обобщенные результаты эпидемиологических и клинических исследований по изучению применения 
L-карнитина в лечении рака молочной железы. 
 
The incidence of breast cancer in the world in 
general and in Ukraine in particular is growing. In 
2017, in Ukraine the incidence reached 16 percent of 
female population, for which, the breast cancer 
ranked first in structure of oncological incidence 
among women. 
In analysing the data of the National Cancer 
Registry of Ukraine, it should be noted, that in 
comparison with 2014 year, the prevalence rate of 
breast cancer in 2016 has increased by 5,1%, that 
indicates importance of improvement diagnostic pro-
cedures and methods of treatment it [1].  
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Studying the scientific literature on this subject, 
we noticed that there is a strong biological rela-
tionship between obesity and a poor outcome of 
breast cancer. And having analysed the date of Mi-
nistry of Health in Ukraine it can be concluded, that 
about 26% of women in 2017 year had overweight 
or obesity [2]. More depressing results show WHO - 
in 2016 39% of adults over 18 years (39% of men 
and 40% of women) were overweight, while 13% of 
the adult population of the planet (11% of men and 
15% of women) were obese [14]. 
Obesity has a chronic metabolic character, which 
is the result of the interaction of the endogenous 
factors, environmental conditions and lifestyle. En-
dogenous factors could be considered a violation of 
the genetic and hormonal balance. The external con-
ditions and type of lifestyle include irregular rhythm 
nutrition, use of substandard products and sedentary 
lifestyle. Obesity is the first risk factor for metabolic 
syndrome, diabetes type II, cardiovascular disease 
and some forms of cancer, including breast cancer. 
Since overweight is a risk factor for breast can-
cer, there is reason to believe that among patients 
with breast cancer the percentage of obese women is 
higher than in the population. The risk of breast 
cancer in postmenopausal women by 30%, it is more 
than in premenopausal, women with obesity - 50%. 
Furthermore it was proven that obesity is associated 
with poor prognosis in patients with breast cancer, 
regardless of menopausal status, and effectiveness of 
systemic medication breast cancer in patients that 
have overweight is lower than in patients with 
normal BMI [17]. 
Analyzing the statistics, it was noted that patients 
with breast cancer and normal BMI have a longer 
overall and disease-free survival, compared with 
patients with breast cancer and obesity. There is also 
a strong correlation between obesity and the 
involvement of lymph nodes in the cancer process. 
These observations show that obesity can enhance 
the metastatic spread of breast tumors [6, 7]. 
Although obesity is associated with a poor 
outcome in women with breast cancer, it is unclear 
how weight loss after diagnosis will change its cour-
se and results. 
Recently, complementary and alternative medi-
cine (CAM) is widely accepted among patients with 
breast cancer, which may provide several beneficial 
effects including reduction of therapy-associated 
toxicity, improvement of cancer-related symptoms, 
fostering of the immune system, and even direct 
anticancer effects [3]. 
L-carnitine is a metabolite of C₄ oil LC, which is 
involved in the transfer of palm-n-LC through the 
inner membrane into the mitochondrial matrix and is 
a substrate for the formation of ATP molecules. 
Carnitine is a trimethylated amino acid naturally 
synthesized in the liver, brain and kidneys from 
protein lysine and methionine. Several factors, such 
as sex hormones and glucagon, can influence the 
distribution and level of carnitine in tissues [2, 18]. 
In the absence of L-carnitine, the inner mem-
brane of the mitochondria becomes impermeable to 
fatty acids, which entails a chain of various meta-
bolic disorders in the human body. Carnitine has a 
modulating effect on the function of acetylcholine 
excitatory neurotransmitter, glutamate excitatory 
amino acid, insulin growth factor-1 (IGF-1) and nit-
ric oxide (NO) [2]. 
Also proved, that L-carnitine may have a dual 
protective effect by enhancing the energy dynamics 
of the cell and inhibiting cell membrane hype-
rexcitability, which make it an ideal nutrient for 
cancer prevention and treatment [18]. 
Based on the data that are already studied, it can 
be concluded that L-carnitine is the ideal medicine 
for treating the metabolic syndrome in obese people. 
There is a direct relationship between obesity and 
the risk of developing breast cancer. Based on the 
data of literature, it can be argued that this risk 
directly correlates with the severity of the metabolic 
syndrome and with BMI, which causes the urgency 
and need for more in-depth study of this problem. 
This article presents the information of epide-
miological and clinical studies of the influence of 
the body mass index on the effectiveness of breast 
cancer treatment by individualizing therapeutic 
measures taking into account the characteristics of 
patient's metabolism. 
The effectiveness of the prescribing of L-car-
nitine for breast cancers' treatment, as well as the 
effect of BMI on the outcome of the disease is 
proven in epidemiological and clinical studies. 
DSM Chan and co-authors (2014) reported that 
women who have BMI>30 course and outcomes of 
breast cancer are significantly worse than women 
with BMI <30. They proved, that women with BMI> 
30 have the overall relative risk of total mortality 
1.41, women with BMI of 25>30 – 1.07. At the 
same time, for every 5 kg/m² of the increase BMI, 
the risk of both total mortality and mortality from 
breast cancer increased, namely by 18% and 14%, 
respectively [5]. 
M. Protani and co-authors (2010) have shown 
that women with breast cancer, who are suffering in 
obesity, have lower survival rate than women with 
breast cancer without obesity [24]. 
Recently published data of randomized clinical 
reseaches by ML Neuhouser and co-authors (2015) 
demonstrated, that for women>50 years old, with 2 
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and 3 stages of obesity (BMI>35) is typically the 
development of GR+ breast cancer [23]. 
Similarly, B. Pajares et al., who found signifi-
cantly worse results for patients with BMI≥35 
compared with patients with BMI<25, stated that the 
magnitude of the effect depended on the cancer sub-
type (estrogen receptor (ER)/progesterone (PR) 
positive and HER2 negative, HER2 positive, triple 
negative) [21].  
An analysis of the pooled data of the three 
adjuvant studies of the Eastern Cooperative Cancer 
Group showed significantly worse results for pa-
tients with obesity (BMI≥30) than for patients with 
normal BMI with a hormonal receptor-positive di-
sease. And it was noted absence of negative effect of 
obesity on survival in patients with other breast 
cancer subtypes [22]. 
C. Fontanella et al. (2015) studied the effect of 
BMI on different molecular subtypes of breast can-
cer and concluded that in women with ER / PR-
positive and HER2-negative breast cancer, as well as 
with TNBC, the risk of death is significantly higher 
than in other subtypes of cancer. This is because the 
fatty tissue produces an excessive amount of 
estrogen, a high level of which is associated with an 
increased risk of developing breast, endometrial, 
ovarian and some other cancers. It has also been 
proven that the level of adipokine, that promotes cell 
proliferation, increases in the blood with increasing 
of level of fat in organism. And adiponectin, which 
people with obesity have less than people with 
normal BMI, can have antiproliferative effects. Such 
data can serve as evidence of the effect of BMI on 
the course and outcome of breast cancer [16]. 
Yet another proof of influence developing meta-
bolic syndrome on the course and outcome of breast 
cancer was proposed by R. Bhandari et al. (2014). 
They proved, that that the presence of metabolic 
disorders (that is, the metabolic syndrome) is as-
sociated with an increased risk of breast cancer in 
adult women [4]. 
The above data led to the need to investigate 
medicines that contribute to fat burning, such as L-
carnitine. Based on the data provided by Rania 
M. Khalil and co-authors (2013), we can prove the 
positive effect of this medicine on the course and 
outcome of breast cancer. The study showed that pa-
tients who received Tamoxifen with L-carnitine had 
significant decrease of Her-2 / neu and IGF-1 level 
(P<0.05) in the serum compared with patients who 
received only Tamoxifen. Using of L-carnitine led to 
significant decrease Her-2 / neu level in the serum 
(P<0.05) compared to each of the control patients, 
namely, 59.5%. The effect of tamoxifen on IGF-1 
(P<0.05) -decrease its level by 5.4% [9]. 
However, it has been proved that using of L-
carnitine in the treatment of ER+ breast cancer does 
not significantly reduce the level of estradiol, but 
leads to decrease both tumor markers CEA and 
CA15.3 (P <0.05,% decrease by 80.9% and 67,8%, 
respectively) [9]. 
Using of L-carnitine in patients with breast 
cancer and obesity improves the metabolism of fatty 
acids in mitochondria, restores normal mitochondrial 
function and, thus, improves the general condition 
and quality of patients' life [19]. 
Carnitine may also mimic some of the biological 
activities of glucocorticoids, particularily immuno-
modulation, via suppressing TNF-α and IL-12 re-
lease from monocytes (5). L-carnitine as adjuvant 
therapy in cisplatin-treated cancer patients proved a 
beneficial effect in reducing the cisplatin-induced 
organ toxicity [25]. 
It is possible that, the extremely lipophilic nature 
of carnitine may be responsible for the decrease in 
EGF binding [10]. Carnitine may insert in the cell 
membrane and/or interact with one of the many 
cellular enzymes having lipid substrates or cofactors. 
In addition, carnitine may interact directly with the 
EGFR [15]. 
Experimental evidence is available showing that 
active forms of oxygen may induce the ligand-
independent phosphorylation of the EGFR activating 
Her-2/neu. Moreover, the expression of the receptor 
is induced in conditions of oxidative stress [20]. 
L-carnitine, via its free radical scavenging and 
antioxidant properties, may inhibit ROS-mediated 
EGFR phosphorylation. It has been found that 
palmitoyl-carnitine can inhibit the activity of heart 
and brain protein kinase C in a competitive manner 
and subsequent phosphorylation of the EGFR [8]. 
Although the tumor markers and IGF-1 showed 
no significant difference in TAM-treated patients 
before and after administration of L-CAR, there was 
a tendency to decline it after L-CAR supplemen-
tation [9]. 
The results of the above studies became a pre-
requisite for conducting clinical studies aimed at 
establishing the role of L-carnitine in the treatment 
of breast cancer. To date, the search in the online 
clinical research registration system Clini-
calTrials.gov using key words L-carnitine + breast 
cancer has revealed several studies evaluating the 
efficacy and safety of L-carnitine in the treatment of 
breast cancer patients [9]. Analyzing the obtained 
results, we can conclude that L-carnitine was the 
medicine of choice for neuropathies, as a con-
sequence of chemotherapy, in patients with breast 
cancer [13]. 
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CONCLUSIONS 
L-carnitine is widely used in clinical practice. 
However, recently this medicine causes growing 
interest among oncologists. In a number of studies, 
L-carnitine has proven itself as a medicine that 
capable, during the preoperative systemic antitumor 
therapy, to increase its effectiveness  compared  with  
 
 
standard neoadjuvant systemic antitumor therapy. 
To date, there are several clinical studies that are 
reseaching using L-carnitine in various malignant 
tumors, the results of which are the basis for further 
in-depth study of the effect of the medicine in the 
treatment of malignant neoplasms. 
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